Evidence map›Paper›PMID 41008631›Full record

ArticleBiomolecules2025

EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage.

Abhishek Mishra, Marcus de Bourg, Rawand S Mohamed, Md Abdul Hye Khan, Tsigereda Weldemichael, Donald J Johann, Samaneh Goorani, Shobanbabu Bommagani, Darin E Jones, Anders Vik and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abhishek MishraDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0003-2071-5348
Marcus de BourgDepartment of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, 0316 Oslo, Norway.
Rawand S MohamedDepartment of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, 0316 Oslo, Norway.
Md Abdul Hye KhanDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Tsigereda WeldemichaelDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-2410-7051
Donald J JohannDepartment of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Samaneh GooraniDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Shobanbabu BommaganiDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Darin E JonesDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0003-1581-3453
Anders VikDepartment of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo, 0316 Oslo, Norway.ORCID 0000-0002-7864-3271
John D ImigDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-9668-2899

Funding

Arkansas Biosciences Institute N/AArkansas Research Alliance N/ANIDDK NIH HHS DK103616NIDDK NIH HHS R01 DK103616
6 · The paper itself

Abstract

backgroundThis study investigates how sorafenib induces toxicity in glomerular cells and examines the protective role of 8,9-epoxyeicosatrienoic acid (8,9-EET) analogs in reducing this kidney damage.

methodsHuman renal mesangial cells (HRMCs) and podocytes were treated with no treatment, sorafenib alone, or sorafenib combined with 8,9-EET analogs. Cell viability and apoptosis were measured in both cell types.

resultsSorafenib (1-10 µM) lowered cell viability and increased caspase 3/7 activity in a dose-dependent way in HRMCs and podocytes. Five of twenty 8,9-EET analogs significantly enhanced cell survival and decreased apoptosis. RNA sequencing showed that sorafenib altered 1244 genes, including those involved in cell cycle and the Raf/MEK/ERK pathway. The 8,9-EET analog MDB-52a raised ANGPTL4 levels, linked to metabolism and vascular health, and reduced ACTA2, which could activate protective pathways. Nephroseq data correlated these gene changes with glomerulosclerosis.

conclusionsMDB-52 appears to counteract gene disruptions and protect against sorafenib-induced kidney damage. Overall, 8,9-EET analogs targeting glomerular cells could be potential therapeutic agents to lessen sorafenib-related nephrotoxicity.

Indexed as

Mesangial CellsPodocytesSorafenibAngiopoietin-Like Protein 4ApoptosisCell SurvivalHumansAngiopoietin-Like Protein 4ANGPTL4 protein, humanSorafenibepoxylipidsmesangial cellsnephrotoxicityonconephrologypodocytes

Identifiers

PMID41008631
PMCPMC12467510

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.